Astrazeneca (AZN) Operating Income (2009 - 2026)

Astrazeneca (AZN) has reported Operating Income for 18 consecutive years, with $4.2 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income rose 15.57% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $14.3 billion (up 35.53% YoY), while the FY2025 annual figure was $13.7 billion, up 37.39% from the prior year.
• Operating Income came in at $4.2 billion for Q1 2026 at Astrazeneca, up from $3.0 billion in the prior quarter.
• The five-year high for Operating Income was $4.2 billion in Q1 2026, with the low at $539.0 million in Q2 2022.
• Average Operating Income over 5 years is $2.3 billion, with a median of $2.5 billion recorded in 2023.
• The largest YoY upside for Operating Income was 474.66% in 2022 against a maximum downside of 52.17% in 2022.
• Year by year, Operating Income stood at $1.1 billion in 2022, then gained by 12.8% to $1.2 billion in 2023, then surged by 64.99% to $2.0 billion in 2024, then soared by 46.27% to $3.0 billion in 2025, then jumped by 42.58% to $4.2 billion in 2026.
• According to Business Quant data, Operating Income over the past three periods registered $4.2 billion, $3.0 billion, and $3.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.